Clinical Trials | February 19, 2026
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
Company to launch product after the expiry of semaglutide patent in India
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
Adverse events were consistent with valbenazine’s established safety profile
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
